1. Home
  2. CHCO vs DNTH Comparison

CHCO vs DNTH Comparison

Compare CHCO & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo City Holding Company

CHCO

City Holding Company

HOLD

Current Price

$119.53

Market Cap

1.8B

Sector

Finance

ML Signal

HOLD

Logo Dianthus Therapeutics Inc.

DNTH

Dianthus Therapeutics Inc.

HOLD

Current Price

$39.87

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CHCO
DNTH
Founded
1957
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.8B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CHCO
DNTH
Price
$119.53
$39.87
Analyst Decision
Hold
Strong Buy
Analyst Count
3
9
Target Price
$128.33
$68.00
AVG Volume (30 Days)
103.9K
646.6K
Earning Date
01-22-2026
11-05-2025
Dividend Yield
2.92%
N/A
EPS Growth
11.27
N/A
EPS
8.68
N/A
Revenue
$307,880,000.00
$3,078,000.00
Revenue This Year
$10.45
N/A
Revenue Next Year
$3.18
N/A
P/E Ratio
$13.74
N/A
Revenue Growth
6.33
N/A
52 Week Low
$102.22
$13.37
52 Week High
$133.59
$45.46

Technical Indicators

Market Signals
Indicator
CHCO
DNTH
Relative Strength Index (RSI) 38.18 41.78
Support Level $118.43 $40.79
Resistance Level $124.43 $43.40
Average True Range (ATR) 2.49 1.73
MACD -0.70 -0.47
Stochastic Oscillator 13.79 16.53

Price Performance

Historical Comparison
CHCO
DNTH

About CHCO City Holding Company

City Holding Co is a financial holding company. The company conducts its principal activities through its wholly-owned subsidiary, City National Bank of West Virginia (City National). Through the bank, it provides banking, trust and investment management, and other financial solutions through its network of banking offices located in the states of West Virginia, Virginia, southeastern Ohio, and Kentucky. It offers various products and services such as overdraft facilities, savings accounts, credit cards and debit cards, loans for various purposes, investment advisory, securities brokerage, insurance products, and others. The company's business activities are currently limited to one reportable business segment, which is community banking.

About DNTH Dianthus Therapeutics Inc.

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.

Share on Social Networks: